Option chain shows key data for Zivo Bioscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Zivo Bioscience.

Zivo Bioscience (OTC:ZIVO) Stock, Option Chain

Zivo Bioscience

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI (New Dietary Ingredient, and Skin Health.

Long Ideas

News

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

OCFC

SFBC

ZIVO

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

$2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

Intraday Update

Movers

ACCD

AULT

BENF

BROG

BTTR

BTWN

CMBM

CNTB

EURN

FSLY

GROM

IPDN

ISPO

LGVN

MKUL

MNTS

MSGM

MXCT

NBTX

NKGN

OGEN

OKYO

Grupo Aeroportuario del Centro NorteB de CV

OMAB

ORTX

RIVN

SGML

SNES

VEON

VINO

VSME

WHLR

XRTX

Gainers


	Orchard Therapeutics plc  (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan&#39;s Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.


Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

APPH

BRCC

SMFL

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 5 Defensive Stocks Which Could Rescue Your Portfolio For July

ZIVO BIOSCIENCE INC by Zivo Bioscience, Inc.

Zivo Bioscience Inc

Zivo Bioscience Inc Warrants (29/04/2026)

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 10 years by 3.55% on an annualized basis producing an average annual return of 14.53%. Currently, Caterpillar has a market capitalization of $179.01 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 10 years ago, it would be worth $390.57 today based on a price of $366.04 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734736508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has outperformed the market over the past 5 years by 6.51% on an annualized basis producing an average annual return of 19.48%. Currently, Morgan Stanley has a market capitalization of $198.32 billion. 
Buying $1000 In MS: If an investor had bought $1000 of MS stock 5 years ago, it would be worth $2,433.75 today based on a price of $123.10 for MS at the time of writing.
<h3>Morgan Stanley's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734735609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

JIADE LIMITED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) (the "Company"), a company that specializes in providing one-stop comprehensive education supporting services to adult education institutions, today announced that the Company received a &nbsp;letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.&nbsp;

JDZG

JIADE Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 15 years by 4.58% on an annualized basis producing an average annual return of 16.26%. Currently, Modine Manufacturing has a market capitalization of $6.24 billion. 
Buying $100 In MOD: If an investor had bought $100 of MOD stock 15 years ago, it would be worth $958.79 today based on a price of $118.89 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734734710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Modine Manufacturing 15 Years Ago Would Be Worth This Much Today

On December 19, 2024, it was reported that Senator Markwayne Mullin executed a purchase of iShares MSCI Eurozone ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/EZU#BATS">EZU</a>) stock, valued between $100,001 and $250,000. The transaction, recorded in the December filing, was made on December 19, 2024.
At the time of writing, iShares MSCI Eurozone ETF shares are trading up 0.55% at $47.25.
<h3>Senator&#39;s Recent Trading Activity</h3>
In the past three years, Markwayne Mullin made 211 stock trades totaling more than $5.20 million. The largest trades involved stocks like Russell 1000 Ishares ETF and Invesco Actively Managed Exchange-Traded Fund Trus Invesco High Yield Select ETF. Their most notable trades made recently include key transactions:
<ul>
<li>Invesco Actively Managed Exchange-Traded Fund Trus Invesco High Yield Select ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/HIYS#BATS">HIYS</a>): $250,001 - $500,000 Purchase</li>
<li>iShares Core MSCI EAFE ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEFA#BATS">IEFA</a>): $100,001 - $250,000 Purchase</li>
<li>iShares MSCI Eurozone ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/EZU#BATS">EZU</a>): $100,001 - $250,000 Purchase</li>
</ul>
Here&#39;s a summary of Markwayne Mullin&#39;s recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>iShares Core MSCI EAFE ETF</td>
<td>IEFA</td>
<td>STOCK</td>
<td>$100,001 - $250,000</td>
<td>P</td>
<td>2024-11-27</td>
</tr>
<tr>
<td>iShares Core MSCI Emerging Markets ETF</td>
<td>IEMG</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-11-27</td>
</tr>
<tr>
<td>iShares MSCI Eurozone ETF</td>
<td>EZU</td>
<td>STOCK</td>
<td>$100,001 - $250,000</td>
<td>P</td>
<td>2024-11-27</td>
</tr>
<tr>
<td>Invesco Actively Managed Exchange Traded</td>
<td>&nbsp;</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>P</td>
<td>2024-11-12</td>
</tr>
<tr>
<td>Pimco Commoditiesplus Strategy Fund Class I-2</td>
<td>PCLPX</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S (Partial)</td>
<td>2024-11-12</td>
</tr>
</tbody>
</table>
<a href="https://www.benzinga.com/gov-trades?utm_source=insights-govtrades" rel="noopener noreferrer" target="_blank"><img alt="Gov Trades Image" src="https://www.benzinga.com/files/images/story/2024/1734714046_0.png" style="height:auto; max-width:100%" /></a>
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn&#39;t be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Government

Politics

General

HIYS

IEFA

This Senator Just Bought Up To $250K In iShares MSCI Eurozone ETF Stock

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 5 years by 21.25% on an annualized basis producing an average annual return of 34.22%. Currently, Murphy USA has a market capitalization of $10.53 billion. 
Buying $100 In MUSA: If an investor had bought $100 of MUSA stock 5 years ago, it would be worth $435.98 today based on a price of $519.99 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734733816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MUSA

$100 Invested In Murphy USA 5 Years Ago Would Be Worth This Much Today

SkyBridge Capital founder Anthony Scaramucci has described Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) current price action as part of its typical cycle.
What Happened: In an <a href="https://x.com/Scaramucci/status/1870118849959399556">X</a> post on Friday, he explained that Bitcoin is purging leveraged, short-term momentum trades, a normal phenomenon in its market evolution.
However, Scaramucci also suggested that some altcoins may have experienced their "last hurrah" and could be done for good.
Meanwhile, crypto entrepreneur JC X <a href="https://x.com/Scaramucci/status/1870118849959399556">believes</a> human behaviour remains consistent: when Bitcoin surges, investors feel wealthier and take on more risks, often chasing gains in altcoins due to FOMO. This dynamic suggests altcoins may still have another rally in store.
In an interview, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42491094/anthony-scaramucci-upgrades-his-lamborghinibut-not-at-the-cost-of-selling-bitcoin-why-would-i-sell">Scaramucci expressed optimism</a> about Bitcoin&#8217;s future, stating he would never sell his holdings for luxury purchases. He emphasized Bitcoin's potential to attract <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378636/scaramucci-bitcoin-is-a-volatile-asset-but-ready-for-prime-time-institutional-investing">mainstream institutional investment.</a>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42617815/are-microstrategys-bitcoin-purchases-on-hold-in-january">Are MicroStrategy&#8217;s Bitcoin Purchases On Hold In January?</a>
Why It Matters: Cathie Wood of ARK Invest remains bullish on Bitcoin, projecting a price of $1.5 million by 2030, citing its <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42609380/cathie-wood-says-bitcoin-is-more-scarce-than-gold-predicts-ma-surge-under-trump-2-0">scarcity compared to gold</a>. 
A 10x Research report highlighted macroeconomic challenges, including the Federal Reserve's hawkish stance, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42612972/bitcoins-2025-outlook-suddenly-looks-uncertain-heres-why">signaling a cautious year ahead</a> for traders and investors.
An expert from Foresight Ventures noted that Bitcoin's recent pullback marks its first significant correction since post-election euphoria. 
The analyst stated that <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42614273/bitcoin-crashes-10-ethereum-xrp-down-18-dogecoin-craters-28-what-is-going-on">20% corrections are typical</a> in bull markets, serving as consolidations rather than trend reversals.
Read Next: &nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42613106/have-risk-appetite-here-are-5-cryptos-that-could-make-your-christmas-merry">Have Risk Appetite? Here Are 5 Cryptos That Could Make Your Christmas Merry</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Anthony Scaramucci: Bitcoin's Moves Are 'Normal,' But Some Altcoins May Have Had Their 'Last Hurrah'

WIIM

Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.

Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), alleging the company violated <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40921732/applied-therapeutics-stock-soars-as-fda-scraps-panel-meeting-for-its-inherited-metabolic-disorder" rel="noreferrer noopener">federal securities laws</a>.
The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40078613/rare-disease-focused-applied-therapeutics-lead-candidate-govorestat-has-blockbuster" rel="noreferrer noopener">Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside</a>
The class action covers investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024.
Central to the lawsuit are claims that the company touted positive results from its Phase 3 INSPIRE trial for govorestat for Galactosemia, without <a target="_blank" href="https://www.benzinga.com/24/11/42241059/regulatory-setback-for-applied-therapeutics-lead-program-fda-highlights-deficiencies-in-clinical-application" rel="noreferrer noopener">disclosing significant issues</a>. Bloomberg Law published a copy of the lawsuit online.
Allegations <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/AlexandruetalvAppliedTherapeuticsIncetalDocketNo124cv09715SDNYDec?doc_id=X6AM5BLRTI48QBRMPF9SKEGPKV0" rel="noreferrer noopener">include</a> problems with electronic data capture and dosing errors during the dose-escalation phase of the study, which were concealed from investors.
Investor confidence began to erode on November 27, 2024, when Applied Therapeutics received an FDA Complete Response Letter (CRL).
The CRL indicated that the agency could not approve the company's New Drug Application for govorestat in its current form, citing deficiencies in the clinical application.
Following the disclosure, Applied Therapeutics' stock price dropped sharply, which worsened after the company <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001697532/000095017024132306/aplt-20241202.htm" rel="noreferrer noopener">disclosed</a> receiving a warning letter from the FDA on December 2 highlighting unresolved clinical trial issues.
The FDA's warning letter pointed to electronic data capture problems and a dosing error that resulted in lower-than-targeted doses for some patients during the trial's early phase.
While Applied Therapeutics claims to have addressed these issues through detailed records and prior communications with the agency, investors reacted negatively to the revelations, further eroding the stock's value.
The lawsuit seeks to recover damages for investors who purchased shares at artificially inflated prices, alleging that the company's failure to provide accurate and complete information misled the market.
On Friday, Applied Therapeutics named John Johnson as executive chairman and announced that Shoshana Shendelman has stepped down as Chair and CEO. The company named Les Funtleyder, Applied Therapeutics' CFO, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42613049/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman" rel="noreferrer noopener">as the interim CEO</a>.
RBC Capital analyst maintains Applied Therapeutics with a Sector Perform, lowering the price target from $4 to $1.5.
Price Action: APLT stock closed lower by 13.7% to $0.87 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42614476/whats-going-on-with-kroger-stock-after-revealing-5-billion-buyback" target="_blank" rel="noreferrer noopener">Kroger Launches $5 Billion Accelerated Share Repurchase: Details</a></li>
</ul>

Biotech

Health Care

Legal

APLT

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 10 years by 27.08% on an annualized basis producing an average annual return of 38.07%. Currently, Comfort Systems USA has a market capitalization of $15.61 billion. 
Buying $100 In FIX: If an investor had bought $100 of FIX stock 10 years ago, it would be worth $2,552.04 today based on a price of $438.44 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734732908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Comfort Systems USA 10 Years Ago Would Be Worth Today

Stran &amp; Company, Inc. ("Stran" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAGW#NASDAQ">SWAGW</a>), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced that on December 17, 2024, it received a letter from the Listing Qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), issuing a Staff delisting determination (the "Staff Determination"). The Staff Determination noted that the Staff had notified the Company on June 21, 2024, August 23, 2024 and November 21, 2024 that the Company did not comply with Nasdaq Listing Rule 5250(c)(1) (the "Filing Rule") because the Company had not filed its Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024, and September 30, 2024 (the "Forms 10-Q") with the Securities and Exchange Commission (the "SEC"). The Staff Determination noted that, based on the Staff's review and the materials submitted on August 20, 2024, the Staff granted the Company an exception until December 16, 2024 to regain compliance with the Filing Rule. The Staff Determination stated that the Company had not met the terms of the exception. Specifically, the Company has not filed the Forms 10-Q as required by the Filing Rule. The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company's common stock.

SWAG

SWAGW

Stran & Company Receives Nasdaq Staff Delisting Determination

Jiayin Group Inc. ("Jiayin" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>), a leading fintech platform in China, today announced that it entered into a definitive agreement on December 17, 2024 to purchase certain commercial property located in Shanghai, China (the "Commercial Property") of approximately 43,500 square meters for total cash consideration of approximately RMB1.35 billion. The completion of the purchase is subject to customary closing conditions. The Commercial Property will primarily be used as the Company's new headquarters to meet the demand arising from the continuing growth of the Company's businesses.

JFIN

Jiayin Group Announces Purchase Of Commercial Property Located In Shanghai, China For Total Cash Consideration Of ~RMB1.35 Billion

Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a target="_blank" href="https://www.benzinga.com/government/24/08/40554768/taiwan-semiconductor-ramps-up-overseas-investments-with-1-95b-in-subsidies-eyes-long-term-growth" rel="noreferrer noopener">debut plant in</a> Kumamoto, Japan, will start commercializing by the end of 2024.
Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) and Denso Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOF#OTC">DNZOF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOY#OTC">DNZOY</a>) will be the Taiwanese contract chipmaker&#8217;s initial customers, Technode <a target="_blank" href="https://technode.com/2024/12/19/tsmcs-kumamoto-plant-to-supply-initial-output-to-sony-and-denso/" rel="noreferrer noopener">cited</a> JASM (Taiwan Semiconductor&#8217;s Japanese subsidiary) President Yuichi Horita from a Taiwanese media outlet.
Horita expects Taiwan Semiconductor&#8217;s production line in Japan to align with the quality of those in Taiwan.
The first Kumamoto plant focuses on 22 nm,28 nm, 12 nm, and 16nm processes, while the second will produce 6 nm and 7nm process chips, as planned.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/12/42552200/sony-semiconductor-hits-20-billion-image-sensor-shipments-plans-expansion" rel="noreferrer noopener">Sony Semiconductor Hits 20 Billion Image Sensor Shipments, Plans Expansion</a>
Construction of the second Kumamoto plant will likely begin in the first quarter of 2025, with mass production scheduled by the end of 2027.
The combined monthly production capacity of the two plants will likely exceed 100,000 wafers.
The Japanese government <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41939018/japan-increases-semiconductor-funding-as-us-trade-policies-pressure-taiwan-semiconductor" rel="noreferrer noopener">earmarked over $64.9 billion</a> to consolidate its semiconductor and artificial intelligence (AI) positions, taking a cue from the U.S. and China. Taiwan Semiconductor&#8217;s Arizona fab, worth $20 billion, will produce <a target="_blank" href="https://www.benzinga.com/media/24/12/42514266/taiwan-semiconductor-unveils-20-billion-arizona-chip-fab-apple-named-key-customer" rel="noreferrer noopener">4-nanometer chips by 2025</a>.
Currently, 92% of the most advanced chips are made in Taiwan.
Japan&#8217;s semiconductor package totals over 10 trillion yen and aims to drive public and private investment of over 50 trillion yen by fiscal 2030.
Taiwan Semiconductor is eyeing a second facility in Japan&#8217;s Kumamoto, following its initial $8.6 billion wafer factory in the region. The company plans to invest $13.5 billion in the project.
The chipmaker is also plotting a third high-tech chip production facility worth $20 billion in Kumamoto to manufacture 3 nm chips.
Taiwan Semiconductor chair and CEO&nbsp;C.C. Wei <a target="_blank" href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" rel="noreferrer noopener">expects advanced robots</a> and AI-powered drones to be key growth drivers.
Taiwan Semiconductor stock surged 92% year-to-date.
Investors can gain exposure to the semiconductor sector through VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>).
Price Action: TSM stock closed higher by 1.32% to $197.21 on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/24/12/42554393/disneys-marvel-rivals-game-hits-20-million-players-proves-superhero-power-still-reigns" target="_blank" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a></li>
</ul>
Photo by Sundry Photography on Shutterstock

Tech

Media

DNZOF

DNZOY

Sony Group Corporation American Depositary Shares

SONY

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Taiwan Semiconductor Expands in Japan: Sony and Denso Among First Customers

Procaps Group, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly appointed Board members include:
<ul>
<li>Mr. Alejandro Weinstein, Executive Chairman of the board</li>
<li>Mr. Nicolas Weinstein</li>
<li>Mr. Ernesto Carrizosa</li>
<li>Mr. Jose Frugone</li>
</ul>
The company also acknowledges the resignation of Mr. David Yanovich from the Board of Directors. Procaps expresses its gratitude to Mr. Yanovich for his valuable contributions and dedication during his tenure.
The Board of Directors will be composed of Alejandro Weinstein, José Minski, Alberto Eguiguren, Nicolas Weinstein, Ernesto&nbsp;Carrizosa and Jose Frugone.

Management

PROC

Procaps Group Appoints Alejandro Weinstein, Executive Chairman Of The board

Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>, "the Company", "Exicure"))), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the "Change of Control"), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. ("HiTron"), a publicly listed company (KOSPI) in South Korea. This investment is expected to close within a few days depending on regulatory approvals. Also, on December 19, 2024, the Board of Directors (the "Board") of the Company changed the authorized number of directors comprising the Board to nine directors and appointed four new directors to the Board and two officers to the Company.
The total investment from HiTron will be $10 million after the initial investment of $1.3 million closed in November. The share issuance price for HiTron is $3 per share per the common stock purchase agreement that was signed in early November, and once the second investments closes, HiTron will become Exicure's largest shareholder, owning over 50% of the Company. On December 17, 2024, HiTron completed the acquisition of Exicure's management rights through the appointment of board members.

Financing

Contracts

XCUR

Exicure Announces Shareholders Approve $8.7M Equity Financing From HiTron Systems

Strategic Investment Results in Mission-Aligned Investor and Supporter
Rumble Will Use $250 Million of Proceeds to Further Solidify Balance Sheet and Accelerate Growth Initiatives
Remaining Proceeds Will Be Used to Fund Self Tender Offer for up to 70 Million of Rumble's Class A Common Stock to Provide Liquidity to Stockholders at Same Price as Tether Investment
LONGBOAT KEY, Fla., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) ("Rumble" or the "Company"), the video-sharing platform and cloud services provider, announced today that it has entered into a definitive agreement for a strategic investment of $775 million from Tether ($USDT) ("Tether"), the largest company in the digital assets industry and the most widely used dollar stablecoin across the world with more than 350 million users. Over the last few years, Tether has become one of the most recognized symbols for financial inclusion.
The Company will use $250 million of the proceeds to support growth initiatives and the remaining proceeds to fund a self tender offer for up to 70 million of its Class A Common Stock, at the same price ($7.50 per share) as Tether's investment. Following the completion of the transaction, Chris Pavlovski, Rumble's Chairman and CEO, will retain his controlling stake in the Company.

$USDT

Rumble Announces $775M Strategic Investment From Tether;  Rumble CEO Retains Controlling Stake; Will Use $250M Of The Proceeds To Support Growth Initiatives And The Remaining Proceeds To Fund A Self Tender Offer For Up To 70M Of Its Class A Common Stock, Or $7.50 Per Share As Tether's Investment

Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $180.8, a high estimate of $210.00, and a low estimate of $145.00. This current average reflects an increase of 4.93% from the previous average price target of $172.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732091_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Chart Industries's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$201.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Gregory Lewis</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Pavel Molchanov</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$207.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$198.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$146.00</td>
<td>$151.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chart Industries. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Chart Industries compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Chart Industries's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Chart Industries's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GTLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chart Industries analyst ratings.</a>
<h2>About Chart Industries</h2>
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.
<h3>Key Indicators: Chart Industries's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Chart Industries showcased positive performance, achieving a revenue growth rate of 18.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Chart Industries's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chart Industries's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.17%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Chart Industries's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.66%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.34, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GTLS

Analyst Expectations For Chart Industries's Future

Throughout the last three months, 15 analysts have evaluated Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.6, with a high estimate of $75.00 and a low estimate of $33.00. Marking an increase of 58.07%, the current average surpasses the previous average price target of $33.91. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732084_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Doximity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$49.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$45.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Doximity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Doximity compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Doximity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Doximity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Doximity analyst ratings.</a>
<h2>All You Need to Know About Doximity</h2>
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
<h3>Financial Insights: Doximity</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Doximity's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.44%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Doximity's net margin is impressive, surpassing industry averages. With a net margin of 32.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Doximity's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of 4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCS

Forecasting The Future: 15 Analyst Projections For Doximity

Throughout the last three months, 5 analysts have evaluated Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.8, along with a high estimate of $12.00 and a low estimate of $2.00. This current average has increased by 74.55% from the previous average price target of $2.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732063_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rigetti Computing. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rigetti Computing. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rigetti Computing compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Rigetti Computing's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Rigetti Computing's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RGTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rigetti Computing analyst ratings.</a>
<h2>Unveiling the Story Behind Rigetti Computing</h2>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
<h3>Rigetti Computing: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Rigetti Computing's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -23.41%. This indicates a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Rigetti Computing's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -623.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rigetti Computing's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -12.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Rigetti Computing's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.28%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Rigetti Computing's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGTI

The Analyst Verdict: Rigetti Computing In The Eyes Of 5 Experts

Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.55, along with a high estimate of $8.00 and a low estimate of $4.25. Witnessing a positive shift, the current average has risen by 6.73% from the previous average price target of $5.20.
<img src="https://www.benzinga.com/files/images/story/2024/1734732051_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Lumen Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bora Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$4.25</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$6.50</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lumen Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lumen Technologies compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Lumen Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lumen Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LUMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lumen Technologies analyst ratings.</a>
<h2>Discovering Lumen Technologies: A Closer Look</h2>
With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 has shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
<h3>Lumen Technologies: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: Lumen Technologies's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -11.54%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Lumen Technologies's net margin excels beyond industry benchmarks, reaching -4.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Lumen Technologies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -36.63%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Lumen Technologies's ROA excels beyond industry benchmarks, reaching -0.44%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 55.03, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LUMN

What 5 Analyst Ratings Have To Say About Lumen Technologies

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Super Micro Computer (NASDAQ:<a href="https://investorplace.com/stock-quotes/smci-stock-quote/">SMCI</a>) stock is a hot topic among traders on Monday as the company <a href="https://qz.com/super-micro-computer-stock-sp-500-ai-1851343791">joins the S&amp;P 500</a> today.



This comes as shares of SMCI stock have seen incredible gains over the last year due to the artificial intelligence (AI) boom. That has Super Micro Computer stock up more than 1,000% over the prior 12 months.



With that increasing value comes more recognition, which has earned the company its spot on the S&amp;P. A key point of interest for investors is the company&rsquo;s computer servers and infrastructure.



With the increasing demand for AI comes more need for servers. That&rsquo;s something that Super Micro Computer can offer to customers, both in the government and in the private sector.



<h2>SMCI Stock Tied to NVDA Shares</h2>



Adding to this is the connection between Super Micro Computer and Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>). Super Micro Computer uses Nvidia graphics processing units (GPUs) in its servers. These are what power AI.



In addition to Super Micro Computer joining the S&amp;P 500, it could also be up alongside NVDA stock today. The GPU maker is set to <a href="https://investorplace.com/2024/03/nvda-stock-alert-7-things-to-know-before-nvidia-gtc-2024/">start its annual GPU Technology Conference (GTC)</a> later today. This could bring additional boons to SMCI stock.



SMCI stock is up 3.4% as of Monday morning.



Investors will find more of the latest stock market stories below!



We have all of the hottest stock market news worth reading about on Monday! A few examples include what&rsquo;s going on with shares of Globus Maritime&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/glbs-stock-quote/">GLBS</a>), VirnetX Holding&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/vhc-stock-quote/">VHC</a>) and Zivo Bioscience&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/zivo-stock-quote/">ZIVO</a>) stock today. All of that is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/earning-results/2024/03/glbs-stock-earnings-globus-maritime-for-q4-of-2023/">GLBS Stock Earnings: Globus Maritime Beats EPS, Beats Revenue for Q4 2023</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/vhc-stock-earnings-virnetx-holding-for-q4-of-2023/">VHC Stock Earnings: VirnetX Holding Reported Results for Q4 2023</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/">ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023</a></li>
</ul>On the date of publication, William White&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/smci-stock-alert-super-micro-computer-joins-the-sp-500-today/">SMCI Stock Alert: Super Micro Computer Joins the S&amp;P 500 Today</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SMCI Stock Alert: Super Micro Computer Joins the S&P 500 Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zivo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/zivo-stock-quote/">ZIVO</a>) just reported results for the fourth quarter of 2023.<ul><li>Zivo Bioscience reported earnings per share of -96 cents.</li><li>The company reported revenue of $11,800.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/">ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Zivo Bioscience (ZIVO – Research Report) yesterday. The company's shares closed las...

Zivo Bioscience (ZIVO) Gets a Buy from Maxim Group

Warning: ZIVO is at high risk of performing badly

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zivo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/zivo-stock-quote/">ZIVO</a>) just reported results for the first quarter of 2024.<ul><li>Zivo Bioscience reported earnings per share of -47 cents.</li><li>The company reported revenue of $35,720.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/zivo-stock-earnings-zivo-bioscience-for-q1-of-2024/">ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q1 2024

Zivo Bioscience (ZIVO) just unveiled an announcement. Zivo Bioscience, Inc. has implemented new incentive plans to motivate non-employee directors ...

Zivo Bioscience Enhances Equity Incentive Plans for Leadership

Zivo Bioscience (ZIVO) has provided an announcement. ZIVO Bioscience Inc. has expanded its Board of Directors and welcomed Laith Yaldoo as the new ...

Zivo Bioscience Strengthens Board with New Director Appointment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zivo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/zivo-stock-quote/">ZIVO</a>) just reported results for the second quarter of 2024.<ul><li>Zivo Bioscience reported earnings per share of -$2.78.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/zivo-stock-earnings-zivo-bioscience-for-q2-of-2024/">ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q2 2024

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Zivo Bioscience (ZIVO – Research Report). The company...

Maxim Group Keeps Their Hold Rating on Zivo Bioscience (ZIVO)

GLBS

NVDA

SMCI

Press Releases

ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Comments

Zivo Bioscience

Zivo Bioscience (ZIVO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga